knowledge -WSS

knowledge

author：entertainment 2025-09-30 11:07:09 - browse：68893

Principal Deputy FDA Commissioner Janet Woodcock Stefani Reynolds/The New York Times via AP

WASHINGTON — Principal Deputy FDA Commissioner Janet Woodcock will retire early next year from the Food and Drug Administration after helping steer the agency through an historic period of medical advances during nearly four decades in key leadership positions, she confirmed to STAT Thursday.

Woodcock, a doctor with a chemistry degree, joined FDA in 1986 at its biologics center, where she oversaw the approval of the first biotechnology-based treatments for multiple sclerosis and cystic fibrosis. In 1994, she was named director of the drug center, where she played a key role in guiding some of the most impactful changes to the regulation of medicine, according to Trump administration FDA Commissioner Scott Gottlieb.

Woodcock envisioned that antibody drugs would become a backbone of therapy and created a more predictable regulatory path for their review and approval, Gottlieb said. She presided over a major expansion and modernization of the generic drug program, standardizing reviews in a way that allowed the industry to become safer and more robust, and crafted the reform of over-the-counter drug reviews.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Medical experts are missing from AI regulatory conversations

leisure time

Wikipedia

WSS

Arc Institute generative AI designs new CRISPR systems

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Second House panel advances two

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Resistance to cancer drugs: A new genetic explanation

Arc Institute generative AI designs new CRISPR systems

entertainment

knowledge

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

At least 13 dead in Texas as scorching temps continue

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

What does generative AI mean for health care? We asked experts

Case highlights the risks of experimental stem cell therapy

Activists slam private health insurers over coverage restrictions

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Drug repurposing or repositioning? The language matters

The kidney, in all its complexity, is captured in a new atlas

knowledge

Solving academic medical centers' existential crisis

Case highlights the risks of experimental stem cell therapy

Cytokinetics CEO stresses company can launch heart drug on its own

New warning issued for rebooking air travel after delays, cancellations

NVIDIA and Google execs on the future of AI and drug discovery

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

focus

leisure time

Wikipedia

explore